Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route
Keyword(s):
2018 ◽
Vol 53
(2)
◽
pp. 175-176
◽
2015 ◽
Vol 56
(6)
◽
pp. 683-692
◽
Keyword(s):
Keyword(s):
2011 ◽
Vol 68
(5)
◽
pp. 715-721
◽